NEWSSPORTBABESCELEBRITYTVLIVINGREVIEWSFUNCOMMENTMYSTAR
MotoringCars for SaleTravelDiet & FitnessIt's The BusinessCashpointStyleJobsPropertyShopping Star Videos Classified  
 
More Stories

FCUK sells of Nicole brand

FRENCH Connection is selling its Nicole Farhi label and closing most of its US stores as it seeks to return to profit following a widening in annual losses.

RBS elite get a 100% rise

ROYAL Bank of Scotland has awarded investment bankers huge pay increases as it fights to retain staff.

Chinese eye taxi maker

THE struggling maker of London’s black taxi cabs is poised to fall under the control of Chinese group Geely.
Search the Daily Star
Search the entire Daily Star site from here.
Star Forums
Get posting in the Star Forums!
You can join the debate and post your own views in the lively Daily Star Forums!

GLAXO DRUG MOVE

ABOVE: GlaxoSmithKline is devoting more of its research to diseases such as Alzheimer’s
5th February 2010

By Daily Star Reporter

Your Shout ( 0 )

DRUGS giant GlaxoSmithKline is devoting more of its research to diseases such as Alzheimer’s.


The group wants to focus on areas where it can get the best returns on its investment.


It will also spend more on multiple sclerosis and Parkinson’s, but cut back on pain relief and depression.


Chief executive Andrew Witty has increased his target for annual savings by £500million a year, on top of the £1.7billion already planned.


But he gave no details about job losses amid speculation 4,000 roles could go at the company.

» MORE 'IT'S THE BUSINESS' HERE...
Share @:Digg StumbleUpon del.icio.us Newsvine reddit
  Want to Shout? POST A COMMENT  
Print This Page Email To A Friend Contact Us Get RSS  


	







				

				


	

	

	



	

	
		

			

		

	
	

	




	

			  		
				                                

						
				                                

						
				                                

				
		
  	

	
	

	

	

		

			

	

		

			
				
view profile					
			
 

			
				
view profile					
		

		

			
 

		

		

			Join MySTAR now and get interactive with our ever growing online community
		

		

			Learn More